Tarsus Pharmaceuticals Inc

For the period ended Dec 31, 2024. Filed Feb 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 25, 2025

TARS$73.83+4.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Year Ended December 31,
	2024	2023	2022
Revenues:
Product sales, net	$180,059	$14,729	$—
License fees and collaboration revenue	2,894	2,718	25,816
Total revenues	182,953	17,447	25,816
Operating expenses:
Cost of sales	12,826	1,593	—
Cost of license fees and collaboration revenue	—	—	955
Research and development	53,386	50,312	42,624
Selling, general and administrative	237,310	108,700	44,949
Total operating expenses	303,522	160,605	88,528
Loss from operations	(120,569)	(143,158)	(62,712)
Other income (expense):
Interest income	15,014	10,337	3,499
Interest expense	(7,849)	(3,346)	(2,199)
Loss on debt extinguishment	(1,944)	—	—
Other income (expense), net	586	(102)	86
Realized/unrealized (loss) gain on equity investments	(591)	259	(268)
Change in fair value of equity warrants issued by licensee	(201)	117	(501)
Total other income, net	5,015	7,265	617
Loss before income taxes	(115,554)	(135,893)	(62,095)
Benefit from income taxes	—	—	4
Net loss	$(115,554)	$(135,893)	$(62,091)
Unrealized gain (loss) on marketable securities and cash equivalents	181	72	(74)
Comprehensive loss	$(115,373)	$(135,821)	$(62,165)
Net loss per share, basic and diluted	$(3.07)	$(4.62)	$(2.52)
Weighted-average shares outstanding, basic and diluted	37,604,538	29,383,276	24,619,700

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.